Breaking News Instant updates and real-time market news.

NVO

Novo Nordisk

$54.74

0.25 (0.46%)

, ABLX

Ablynx

$25.91

0.85 (3.39%)

06:01
01/08/18
01/08
06:01
01/08/18
06:01

Novo Nordisk offers to acquire Ablynx for up to EUR30.50 per share in cash

Novo Nordisk (NVO) confirms that it made a proposal on December 22, 2017 to acquire Ablynx (ABLX) for EUR 28.00 per share in cash and one CVR with total potential cash payments over time of up to EUR 2.50 per share. This proposal implies a total equity valuation of approximately EUR 2.6 billion1 for Ablynx and represents a premium of up to 60% over Ablynx's share price as of December 6, 2017 of EUR 19.12, which was the day prior to our first proposal, and up to 66% over Ablynx's 3 month VWAP of EUR 18.39 as of 5 January 2018. Novo Nordisk has made a concerted and good faith effort to engage in discussions with Ablynx. This proposal is the second proposal that Novo Nordisk has made to Ablynx's Board of Directors and represents up to approximately a 14% increase over the first proposal. Novo Nordisk regrets that the Board of Directors of Ablynx has so far declined to engage in any discussions, despite the proposals which have been put forward. Novo Nordisk has conducted a deep analysis of Ablynx's business and product portfolio, based on publicly available information, including caplacizumab, ALX-0171, vobarilizumab, its other pipeline products and partnerships. Following that analysis, Novo Nordisk has concluded that combining Ablynx's caplacizumab with Novo Nordisk's strong global haematology franchise and extensive worldwide resources is a compelling opportunity and provides the clearest path to realizing full potential of Ablynx's portfolio in the best interests of all stakeholders, including patients and physicians. The proposed transaction would combine Novo Nordisk's regulatory, scientific and commercial expertise with Ablynx's strong existing medical teams to optimise the development and global commercialisation of caplacizumab.

NVO

Novo Nordisk

$54.74

0.25 (0.46%)

ABLX

Ablynx

$25.91

0.85 (3.39%)

  • 08

    Jan

  • 08

    Jan

NVO Novo Nordisk
$54.74

0.25 (0.46%)

12/01/17
MSCO
12/01/17
UPGRADE
MSCO
Overweight
Novo Nordisk upgraded to Overweight from Equal Weight at Morgan Stanley
12/06/17
BOFA
12/06/17
UPGRADE
BOFA
Buy
Novo Nordisk upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Sachin Jain upgraded Novo Nordisk to Buy citing high visible growth from the GLP-1 franchise and upward sentiment related to oral semaglutide data.
12/29/17
JPMS
12/29/17
UPGRADE
JPMS
Neutral
Novo Nordisk upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Richard Vosser upgraded Novo Nordisk to Neutral and raised his price target for the shares to 290 kroner from 230 kroner. The analyst expects "strong" oral semaglutide Phase III newsflow in 2018. He believes this will overshadow concerns over the long-term growth potential of the company's business.
12/29/17
12/29/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Overweight from Neutral at JPMorgan with analyst James Gordon saying the company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium. 2. PriceSmart (PSMT) upgraded to Outperform from Market Perform at IFS Securities. 3. Novo Nordisk (NVO) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he expects "strong" oral semaglutide Phase III newsflow in 2018. 4. Syntel (SYNT) downgraded to Underperform from Market Perform at Wells Fargo with analyst Ed Caso saying he sees the company's "weak" positioning for the ongoing shift in information technology demand from "legacy" low-cost offshore-centric software services to more onshore-necessary "digital" solutions as dragging down its growth and margins. 5. RioCan REIT downgraded to Sector Perform from Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABLX Ablynx
$25.91

0.85 (3.39%)

11/20/17
BARD
11/20/17
INITIATION
Target $33
BARD
Outperform
Ablynx initiated with an Outperform at Baird
Baird analyst Brian Skorney initiated Ablynx with an Outperform rating, stating it has a host of promising internal assets for diseases with significant unmet needs and a proprietary platform technology. He sees the company well positioned over the next few years as it stands to receive significant milestone payments from big pharma partners. Skorney has a $33 price target on Ablynx shares.
11/20/17
LTCO
11/20/17
INITIATION
Target $30
LTCO
Buy
Ablynx initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter started Ablynx with a Buy rating and $30 price target.
11/20/17
JEFF
11/20/17
NO CHANGE
Target $34
JEFF
Buy
Jefferies puts Buy rating, $34 target on Ablynx at Jefferies
Jefferies analyst Peter Welford says positive Phase III data further boost his belief that caplacizumab for rare blood disorder acquired thrombotic thrombocytopenic purpura is a "potential game-changer" for Ablynx. The analyst believes the drug may become a standard-of-care and he increased his approval probability to 90%. Welford believes caplacizumab's value is underappreciated at current share levels. He has a Buy rating on Ablynx's ADRs with a $34 price target.
11/20/17
11/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Innoviva (INVA) initiated with a Hold at Deutsche Bank. 2. National Vision (EYE) was initiated with an Overweight at Morgan Stanley, an Outperform at Wells Fargo, a Buy at Jefferies and Citi, as well as a Neutral at Goldman Sachs, UBS, and BofA/Merrill. 3. Ablynx (ABLX) was initiated with an Overweight at JPMorgan, an Outperform at Baird, and a Buy at Ladenburg. 4. Blue Apron (APRN) initiated with a Sector Weight at KeyBanc. 5. BP Midstream (BPMP) was initiated with an Overweight at JPMorgan, a Buy at UBS and Citi, an Equal Weight at Morgan Stanley and Barclays, as well as a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

FB

Facebook

$189.35

3.98 (2.15%)

16:50
01/23/18
01/23
16:50
01/23/18
16:50
Hot Stocks
Facebook acquires mobile ID authentication startup Confirm.io »

Confirm.io announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 28

    Feb

ASB

Associated Banc-Corp

$25.90

-0.15 (-0.58%)

, BKMU

BankMutual

$10.85

-0.1 (-0.91%)

16:46
01/23/18
01/23
16:46
01/23/18
16:46
Hot Stocks
Associated receives regulatory approvals to acquire BankMutual »

Associated Banc-Corp…

ASB

Associated Banc-Corp

$25.90

-0.15 (-0.58%)

BKMU

BankMutual

$10.85

-0.1 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

DKL

Delek Logistics

$32.80

0.5 (1.55%)

16:46
01/23/18
01/23
16:46
01/23/18
16:46
Hot Stocks
Delek Logistics raises quarterly dividend by 1.4% to 72.5c »

Delek Logistics Partner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

NTIP

Network-1 Technologies

$2.60

0.1 (4.00%)

, GOOG

Alphabet

$1,169.97

14.16 (1.23%)

16:45
01/23/18
01/23
16:45
01/23/18
16:45
Hot Stocks
Network-1 Technologies receives favorable ruling from federal circuit court »

Network-1 Technologies…

NTIP

Network-1 Technologies

$2.60

0.1 (4.00%)

GOOG

Alphabet

$1,169.97

14.16 (1.23%)

GOOGL

Alphabet Class A

$1,176.17

12.01 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

SIGM

Sigma Designs

$7.00

0.025 (0.36%)

16:45
01/23/18
01/23
16:45
01/23/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Sigma Designs »

Sigma Designs trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$40.06

0.75 (1.91%)

16:44
01/23/18
01/23
16:44
01/23/18
16:44
Hot Stocks
U.S. Steel 'pleased' with Presidential tariffs on certain imports »

United States Steel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

UAL

United Continental

$77.97

1.1 (1.43%)

16:42
01/23/18
01/23
16:42
01/23/18
16:42
Hot Stocks
United Continental says 2017 a 'transition' year »

Says understands that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

AUO

AU Optronics

$4.69

0.03 (0.64%)

16:42
01/23/18
01/23
16:42
01/23/18
16:42
Upgrade
AU Optronics rating change  »

AU Optronics upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGII

Argo Group

$65.10

0.05 (0.08%)

16:41
01/23/18
01/23
16:41
01/23/18
16:41
Hot Stocks
Argo Group reports preliminary pre-tax catastrophe loss of $34M-$38M in Q4 »

Argo Group International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGNX

MacroGenics

$20.25

0.83 (4.27%)

16:40
01/23/18
01/23
16:40
01/23/18
16:40
Hot Stocks
MacroGenics completes interim futility analysis of the Phase 3 SOPHIA trial »

MacroGenicsannounced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$15.59

1.33 (9.33%)

16:38
01/23/18
01/23
16:38
01/23/18
16:38
Upgrade
LG Display rating change  »

LG Display upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$26.75

-0.22 (-0.82%)

16:37
01/23/18
01/23
16:37
01/23/18
16:37
Syndicate
Breaking Syndicate news story on GDS Holdings »

GDS Holdings files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:36
01/23/18
01/23
16:36
01/23/18
16:36
General news
API crude inventories for week of January 19 »

API reports that crude…

NAVI

Navient

$13.44

-0.08 (-0.59%)

16:34
01/23/18
01/23
16:34
01/23/18
16:34
Earnings
Breaking Earnings news story on Navient »

Navient reports Q4 GAAP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

FHN

First Horizon

$20.11

0.01 (0.05%)

16:34
01/23/18
01/23
16:34
01/23/18
16:34
Hot Stocks
First Horizon replaces share repurchase program »

The board of First…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FHN

First Horizon

$20.11

0.01 (0.05%)

16:33
01/23/18
01/23
16:33
01/23/18
16:33
Hot Stocks
First Horizon increases quarterly dividend 33% »

First Horizon National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SD

SandRidge Energy

$19.29

-0.02 (-0.10%)

16:32
01/23/18
01/23
16:32
01/23/18
16:32
Hot Stocks
SandRidge Energy: Not in best interests of holders to accept Ichan's proposal »

SandRidge Energy issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CQP

Cheniere Energy Partners

$31.30

0.41 (1.33%)

16:32
01/23/18
01/23
16:32
01/23/18
16:32
Hot Stocks
Cheniere Energy Partners raises dividend to 50c from 44c »

Cheniere Energy Partners,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

GORO

Gold Resource

$4.97

0.05 (1.02%)

16:32
01/23/18
01/23
16:32
01/23/18
16:32
Hot Stocks
Gold Resource to expand Arista Mine vein system »

Gold Resource announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

TRMK

Trustmark

$33.53

-0.03 (-0.09%)

16:31
01/23/18
01/23
16:31
01/23/18
16:31
Earnings
Trustmark reports Q4 adjusted EPS 48c, consensus 47c »

Gerard R. Host, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

16:30
01/23/18
01/23
16:30
01/23/18
16:30
Options
Preliminary option volume of 22.5M today »

Preliminary option volume…

SBBP

Strongbridge Biopharma

$8.70

0.25 (2.96%)

16:27
01/23/18
01/23
16:27
01/23/18
16:27
Syndicate
Strongbridge Biopharma files to sell 5M shares of common stock »

JMP Securities is acting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$120.00

0.56 (0.47%)

16:26
01/23/18
01/23
16:26
01/23/18
16:26
Technical Analysis
Technical Take: Texas Instruments drops sharply after results »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

COF

Capital One

$105.71

0.22 (0.21%)

16:26
01/23/18
01/23
16:26
01/23/18
16:26
Hot Stocks
Breaking Hot Stocks news story on Capital One »

Capital One reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

JAX

J. Alexander's

$10.20

-0.3 (-2.86%)

16:26
01/23/18
01/23
16:26
01/23/18
16:26
Hot Stocks
J. Alexander's major holders support 99 Restaurants acquisition »

Substantial holders of J.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.